Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893153 | 0.94 | TRPA1 (0.41) | TRPA1HIF1AEPAS1SRPK1 | |
| SCHEMBL893631 | 0.94 | TRPA1 (0.41) | TRPA1SMN1; SMN2 | |
| SCHEMBL894375 | 0.90 | TRPA1 (0.47) | TRPA1HIF1AEPAS1SRPK1KDM4E | |
| SCHEMBL894126 | 0.89 | TRPA1 (0.41) | TRPA1SRPK1SMN1; SMN2 | |
| SCHEMBL894637 | 0.89 | TSHR (0.48) | TRPA1TSHR | |
| SCHEMBL894266 | 0.88 | TRPA1 (0.44) | TRPA1 | |
| SCHEMBL10202210 | 0.87 | TRPA1 (0.41) | TRPA1NAMPTKDM4ETSHRMAPT | |
| SCHEMBL10164614 | 0.87 | TRPA1 (0.37) | TRPA1POLBMAPTSMN1; SMN2 | |
| SCHEMBL894189 | 0.87 | HIF1A (0.40) | TRPA1HIF1AEPAS1SRPK1NAMPT | |
| SCHEMBL10164606 | 0.86 | LMNA (0.40) | TRPA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HIF1A 1598/4885EPAS1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.